Key facts
- This page summarizes Thomas J. Schaefer's Form 4 filing for Arcadia Biosciences, Inc. (RKDA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 05 Feb 2024, 16:29.
Thomas J. Schaefer - 01 Feb 2024 Form 4 Insider Report for Arcadia Biosciences, Inc. (RKDA)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- RKDA
- Reported as of
- 01 Feb 2024
- Net transaction value
- +$1,442
- SEC form
- 4
- Accepted by SEC
- 05 Feb 2024, 16:29:56 UTC
- Prior SEC filing
- 07 Aug 2023
- Next SEC filing
- 20 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- Thomas J. Schaefer, by Attorney-in-fact, Solaeta Chan
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Thomas J. Schaefer filed Form 4 for Arcadia Biosciences, Inc. (RKDA) on 05 Feb 2024.
Change
- Previous filing in this sequence was filed on 07 Aug 2023.
- Current net transaction value: +$1,442.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RKDA
transaction
Common Stock
Purchase
- Transaction value
- $1,442
- Shares
- +700
- Change %
- +97%
- Price
- $2.06
- Shares after
- 1,419
- Date
- 01 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Reflects the purchase of 700 shares of the Issuer's common stock on 2/1/24 at a per share purchase price of $2.06 pursuant to participation in the Issuer's 2015 Employee Stock Purchase Plan ("ESPP"). This transaction is exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of Issuer's common stock.
Footnote F2
The amount includes the 2015 Employee Stock Purchase Plan ("ESPP") purchases, for the purchase periods from February 1, 2021 to February 1, 2024. These transactions were exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of Issuer's Common Stock on the date of each respective purchase.